PYRAMID-ANALYTICS
31.3.2022 16:37:11 CEST | Business Wire | Press release
Experts from Delaware and Pyramid Analytics will explore why and how Decision Intelligence – what’s next in analytics and business intelligence (ABI) – should be introduced into enterprise platforms at the UKISUG Analytics Symposium , an annual event for the independent UK & Ireland SAP User Group being held on 5 April, 2022 at The Vox Conference Centre, Birmingham. The conference offers the opportunity for networking and collaboration among peers specialising in SAP Analytics Cloud, data preparation, platform & database and digital transformation.
UKISUG Analytics Symposium is free to attend. Register here .
Key Points:
- Delaware’s Analytics Lead and Pyramid’s Director of Product Management will discuss Decision Intelligence and how to introduce it into an SAP business and technology ecosystem.
- Delaware implements the Pyramid Decision Intelligence Platform across the UK & Ireland to help organisations leverage the full value of data by providing AI-powered analytics to all decision-makers.
- Both companies have partnerships with SAP and expertise in the SAP technology ecosystem .
- Pyramid Analytics is an official member of the SAP® PartnerEdge® open ecosystem. Pyramid Platform is certified by SAP Certified for SAP BW/4HANA, SAP HANA, and SAP NetWeaver.
Attendees, Mark Your Diaries
Chris Houlder, Analytics Lead at Delaware, and Ian MacDonald, Director of Product Management with Pyramid, will discuss how enterprises running on SAP can best understand their data and how to react to fast-changing conditions, and address the challenges of adopting a holistic platform that works directly on both SAP BW and SAP HANA. The session will also include a demo of the Pyramid Analytics Decision Intelligence platform and how to get more value from these SAP investments. The session begins at 10 a.m. GMT.
Partnership Brings Decision Intelligence to Enterprises Across the UKI
Pyramid Analytics and global IT services company Delaware have a partnership agreement through which the companies jointly sell and implement the Pyramid Platform for decision intelligence and provide consulting services. The partnership puts the Pyramid Platform for decision intelligence into the hands of more than 3,000 Delaware consultants. The Pyramid Platform uniquely combines Data Preparation, Business Analytics, and Data Science in a single Analytics and Business Intelligence (ABI) environment. Leading technology analysts BARC, Dresner Advisory Services, and Gartner rank Pyramid first in critical ABI capabilities .
Pyramid and Delaware have strong partnerships with SAP, the world’s largest provider of Enterprise Application Software. Delaware and Pyramid Analytics jointly deliver solutions enabling customers to integrate sophisticated SAP data sets and non-SAP sources, from a wide range of on-premises and cloud-based data sources, without moving or ingesting the data, through a single decision intelligence platform.
Many of Delaware’s clients have complex landscapes and face challenges pulling together accurate and coherent reporting. Pyramid enables all users, from data scientists to non-technical business users, to maximise their investments in SAP providing for the fastest, direct querying and analytics on BW, BEx, HANA, CDS and IQ, while maintaining the investment in business logic and security designed into SAP — all within a complete point and click, no-code, governed self-service analytics environment.
Quotes
Ian Macdonald, Director of Product Management, Pyramid Analytics : “Business success in today’s dynamic markets requires organizations to react to trends and opportunities in real time with accuracy, speed and scale. Data drives better decisions. However, due to legacy tool limitations, integration issues and data management challenges, many SAP customers struggle to expose all the necessary data to deliver modern self-service analytic capabilities. Pyramid Decision Intelligence Platform allows business users to get more value out of their existing SAP BW and SAP HANA investments, delivering best-in-class functionality and performance that preserves the security and governance inherent in the SAP platform.”
Complete, Unified Decision Intelligence
Pyramid’s Decision Intelligence Platform unifies Data Preparation, Business Analytics, and Data Science on a single, integrated platform. This eliminates the need to use multiple disparate tools and the associated license cost and management complexity. Lower Total Cost of Ownership (TCO), rapid rollout, quicker and direct access to all available data, and industry-leading user adoption means faster time to value. Pyramid’s Decision Intelligence Platform can be deployed on-premises, into a private or public cloud, embedded into other apps or delivered through Managed Services Providers (MSP).
About Delaware
Delaware is a fast-growing, global company that delivers advanced solutions and services to organisations striving for a sustainable, competitive advantage. Delaware guides its customers through their business transformation, applying the ecosystems of its main business partners, SAP and Microsoft. Delaware continues to service its customers afterwards, assuring continuity and continuous improvement. Delaware has over 3000 professionals in 24 offices around the world. For more information, please visit www.delaware.co.uk .
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo .
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include Jerusalem Venture Partners (JVP), Sequoia Capital and Viola Growth. Learn more at Pyramid Analytics .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005705/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom